{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:59:58Z","timestamp":1784091598870,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.nmd.2020.08.355","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:17:24Z","timestamp":1597234644000},"page":"815-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Mortality rates and causes of death in Swedish Myasthenia Gravis patients"],"prefix":"10.1016","volume":"30","author":[{"given":"Elisabet","family":"Westerberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2020.08.355_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0002","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.nmd.2020.08.355_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nmd.2020.08.355_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/ane.13017","article-title":"Lifestyle factors and disease-specific differences in subgroups of Swedish Myasthenia Gravis","author":"Westerberg","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2020.08.355_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/annonc\/mdh155","article-title":"Extrathymic malignancies in patients with thymoma","volume":"15","author":"Evoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jns.2009.11.006","article-title":"Extrathymic malignancies in thymoma patients with and without myasthenia gravis","volume":"290","author":"Owe","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2020.08.355_bib0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000311012","article-title":"Nationwide population-based epidemiological study of myasthenia gravis in taiwan","volume":"35","author":"Lai","year":"2010","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.nmd.2020.08.355_bib0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","article-title":"A national epidemiological study of Myasthenia Gravis in Australia","volume":"19","author":"Gattellari","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"Breiner","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.08.355_bib0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.25068","article-title":"Epidemiology of myasthenia gravis in Northern Portugal: frequency estimates and clinical epidemiological distribution of cases","volume":"54","author":"Santos","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.08.355_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","article-title":"Prevalence of myasthenia gravis in the Catalan county of Osona","volume":"32","author":"Aragones","year":"2017","journal-title":"Neurologia"},{"key":"10.1016\/j.nmd.2020.08.355_bib0012","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A nationwide epidemiological study of myasthenia gravis in Latvia","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0013","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mus.25205","article-title":"Factors affecting outcome in myasthenia gravis","volume":"54","author":"Andersen","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.08.355_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2015.03.018","article-title":"Prognostic factors for exacerbations and emergency treatments in myasthenia gravis","volume":"282","author":"de Meel","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp.64.1.78","article-title":"Mortality and survival in myasthenia gravis: a Danish population based study","volume":"64","author":"Christensen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.nmd.2020.08.355_bib0016","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/jnnp.71.3.352","article-title":"Epidemiology of seropositive myasthenia gravis in Greece","volume":"71","author":"Poulas","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2020.08.355_bib0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.24697","article-title":"Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark","volume":"53","author":"Hansen","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.08.355_bib0018","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mus.26132","article-title":"Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade","volume":"58","author":"Basta","year":"2018","journal-title":"Serbia. Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.08.355_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","article-title":"Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001","volume":"77","author":"Owe","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2020.08.355_bib0020","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.08.355_bib0021","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.2007.118950","article-title":"Neurological care and risk of hospital mortality for patients with myasthenia gravis in England","volume":"79","author":"Hill","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2020.08.355_bib0022","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.08.355_bib0023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10072-014-1659-y","article-title":"Predictors of outcome of myasthenic crisis","volume":"35","author":"Kalita","year":"2014","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.nmd.2020.08.355_bib0024","first-page":"129","article-title":"Clinical profile and outcome of myasthenic crisis in Central Taiwan","volume":"25","author":"Wong","year":"2016","journal-title":"Acta Neurol Taiwan"},{"key":"10.1016\/j.nmd.2020.08.355_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12883-019-1384-5","article-title":"Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0026","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4103\/aian.AIAN_197_19","article-title":"Comorbidities and long-term outcomes in a cohort with myasthenic crisis: experiences from a tertiary care center","volume":"22","author":"Sivadasan","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0027","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.08.355_bib0028","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.nmd.2020.08.355_bib0029","article-title":"The national patient register","year":"2018","journal-title":"Loss Qual Inf"},{"key":"10.1016\/j.nmd.2020.08.355_bib0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.nmd.2020.08.355_bib0031","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish cancer register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0033","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrneurol.2011.14","article-title":"Neuromuscular disease: acute treatment for myasthenia gravis","volume":"7","author":"Gilhus","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0034","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.08.355_bib0035","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1468-1331.2011.03621.x","article-title":"Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study","volume":"19","author":"Liu","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0036","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/ene.12383","article-title":"Myasthenia and risk of cancer: a population-based case-control study","volume":"21","author":"Pedersen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0037","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0404.1984.tb00817.x","article-title":"Heart disease in myasthenia Gravis","volume":"70","author":"Hofstad","year":"1984","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2020.08.355_bib0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0002-9149(92)90688-U","article-title":"Left ventricular function in myasthenia Gravis","volume":"69","author":"Johannessen","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2020.08.355_bib0039","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s000590050023","article-title":"Giant cell myocarditis: diagnosis and treatment","volume":"25","author":"Cooper","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.nmd.2020.08.355_bib0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1440-1789.2012.01345.x","article-title":"Giant cell polymyositis and myocarditis associated with myasthenia gravis and thymoma","volume":"33","author":"Kon","year":"2013","journal-title":"Neuropathology"},{"key":"10.1016\/j.nmd.2020.08.355_bib0041","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JND-180355","article-title":"Pattern of habitual physical exercise in myasthenia Gravis patients","volume":"6","author":"O'Connor","year":"2019","journal-title":"J Neuromuscul Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620305526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620305526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:46Z","timestamp":1760774986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620305526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0960896620305526"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.08.355","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality rates and causes of death in Swedish Myasthenia Gravis patients","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.08.355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}